Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative versus postoperative mFOLFIRINOX for resectable pancreatic ductal adenocarcinoma
ACTRN12624000005550Phase 3Recruiting
- Sponsor
- Epworth HealthCare
- Start
- May 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, irinotecan, folinic acid and fluorouracil in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Epworth HealthCare. Primary endpoint: Overall survival. Started May 2024; status: recruiting.
02
Drugs
oxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12624000005550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000005550.